- Topic
3k Popularity
4k Popularity
21k Popularity
19k Popularity
5k Popularity
67k Popularity
141k Popularity
69k Popularity
1762k Popularity
53k Popularity
- Pin
- 🎉 CandyDrop 5.0: 5 BTC Mega Airdrop is here!
🎁 Total Prize Pool: 5 BTC
📈 Trade any futures pair ≥ 50,000 USDT to earn Candy
👥 Invite friends to unlock more BTC rewards
🗓️ Event Time: June 27, 9:00 – July 11, 9:00 (UTC)
🎯 Max reward per user: 0.01 BTC
👉 Join Now >> https://www.gate.com/candy-drop/detail/BTC-59
⚡ 100% real airdrop — limited time only!
- Gate Alpha 2nd Points Carnival Round 4 Hot Launch! Trade to Share $30,000 MORE & Alpha Points
Trade $MORE to unlock Listing Airdrops + $300K Points Prize Pool!
💰 Total Airdrop Volume: $30,000 MORE, Limited slots—first come, first served!
✅ Total Points: 2 Alpha Points per trade—accumulate points to share the $300K prize pool!
🔥Trade the Hottest On-Chain Assets First
For more information: https://www.gate.com/campaigns/1342alpha?pid=X&c=MemeBox&ch=vxDB0fQ5
- 📢 $MORE is launching on Gate Alpha!
Users will be able to trade Moonveil ( $MORE ) directly via Gate Alpha — Gate's one-stop on-chain trading portal.
🔥Trade the Hottest On-Chain Assets First
https://www.gate.com/alpha
- 🎁 Gate Alpha Airdrop Alert!
To celebrate the listing of $EGL1 on Gate Alpha @GateioAlpha
A limited-time airdrop campaign is now live — with 149,254 EGL1 up for grabs!
First Come, First Served
🔥Trade the Hottest On-Chain Assets First
For more information: https://www.gate.com/campaigns/1355?pid=X&ch=0cykUS3i
- Welcome Kevin_Lee to the Gate Square! 🎉
Looking forward to more great crypto insights from him.
Check out and engage with Kevin_Lee’s latest post!
👉 Post: https://www.gate.com/post/status/11758920
👉 Profile: https://www.gate.com/profile/Kevin%20Lee
Let’s give Kevin_Lee a warm welcome! 👏👏👏
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.